Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (244)	7/7/2002 1:08:23 PM
From: scaram(o)uche	Respond to of 631

[ more VLA-4, Wyeth/Elan ] ditto, not the result of an exhaustive search, but just something that I ran across....... United States Patent 6,407,066 Dressen , et al. June 18, 2002 -------------------------------------------------------------------------------- Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 Abstract Disclosed are pyroglutamic acid derivatives and related compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis. patft.uspto.gov